Friday, July 20, 2018 8:58:38 PM
No. Bankruptcy is a legal process a company or individual goes through which must be approved by a court. NWBO has not filed for bankruptcy. NWBO is not technically bankrupt, nor is there any evidence to suggest that it has even begun the process for filing for bankruptcy.
A conclusory statement without any evidentiary support. If there is overwhelming evidence, then why can it not be posted? Argument invalid.
Another conclusory statement without any evidence to support it. In fact, the evidence presented in the published article suggests that DC-VAX works and does not have serious side-effects. More to the point, Linda did not design the trial so if the trial itself fails, it could hardly be her fault.
Although I am not an expert in this, I am under the impression that this is not an uncommon state of things with small bio-tech startups. The evidence suggests that the stock was manipulated by short sellers. See Smith on Stocks and Washington Post articles or this article on how manipulation is done. Nor is there any explanation for how they could possibly have prevented this from happening or how they were complicit in causing it. Also, there is still shareholder value as long as the stock is trading.
No, I said that the stock price is largely irrelevant [from now] until unblinding. It is relevant to financing but for the most part, it is likely to continue to trade somewhere in the .20s until unblinding. It is unlikely to go much lower because there are a lot of people who seem willing to buy when it drops lower and who feel that the trial will be a success. It is unlikely to go much higher because shorts can manipulate any rally for their own advantage. Until a larger pool of investors becomes interested, the stock is not likely to go anywhere. Whether it is at $0.27 or $0.22 is largely irrelevant.
But it didn’t and as I explained earlier, maintaining that price was never likely to happen. This is a company with no approved products, no revenue, and when it was at $6 a long path ahead to approval. There is no way it can maintain that kind of price when there are lots of people out there who can make a LOT of money manipulating it. The value of this company upon approval is not going to be based on its stock price now. That is why the current price is largely irrelevant. The price after approval is going to be based on the potential market for their products. Also, the price is not sinking fast. Your post from 2 weeks ago at $.23 and now it is selling at $0.223. Not exactly sinking fast.
What makes you think that is the only reason all of us investors are here? I am certainly not here in the hopes that the interim pre-unblinding price goes up or down a few cents. I could not possibly care less about that. I am here because of where I believe that price will be after unblinding and approval. Other people may be here at least in part because they want to support a company that can help people with the most dire cancer to live longer.
Sentiment_stocks already addressed this here so I won’t bother. The real question is why you think that you, with no knowledge in the field and little information about the study, have a better idea about when to conclude the study than do a group of doctors who practice in this field and have been getting all available data for the last 10 years? My personal take is that this company is likely to live or die as a result of this Phase III trial and they want to be sure that they have what they need to get approval. If they need to wait an extra 6-12 months to get from 85% to 95% or whatever, then that is what they will do.
They have discussed this, multiple times. The Spring Refresh provides them with data on how the trial is going. Specifically, it is showing them the existence and properties of the long tail. They NEVER committed to unblinding after the refresh, quite to the contrary, in fact. Once they stop the trial and take the blinders off they can’t restart if they determine that they do not have the data they need to get approval. I am far more concerned about them ending the trial before they secure the data needed for approval than I am with the possibility that they allow it to run a bit longer. Imagine the uproar if they stop the trial prematurely after 10 years and fail to get approval that they could have secured if they had waited a few more months.
The company never said that they were waiting for 36 months. However, assuming that is the goal, then it seems logical that they would want to know what the data looks like prior to unblinding. Why would they pick an arbitrary number of months and unblind without knowing if the data was likely to show what they needed for approval?
You base this on what? Instead of accepting that the people who know what they are talking about actually know what they are talking about you claim without evidence that you know more about their specialty than do they.
And finish with more conclusory statements supported by nothing.
You also forgot to mention your contradictory claim that they are giving themselves bonuses . . . in stock that you claim is worthless.
Let me finish with something written by someone who you should be willing to listen to . . .
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136842794
What they wrote in those press releases was accurate, but if everything mentioned in those releases occurred as described, then what it means is that right now there is a lot of work going on behind the scenes to bring this product to market. The best way to ensure that happens successfully and without compromise is to operate in quiet mode. Everything that we have staked our hopes for a better world on, and our hard-earned money on, is now at the end game. That end game involves a very careful, deliberate process of review, analysis, review, analysis, and then more review and analysis until conclusions are drawn and papers are written and published. It takes a lot of time – perhaps many months – and any misstep along the way can jeopardize the whole thing. That's why silence is golden right now. When companies make meaningless statements like "the process is ongoing" just to appease a restless audience, it can do serious damage and end up exacerbating the perceived problem. Do you think anyone on this board would be satisfied with that kind of statement? Ha, not likely. And saying anything more than that could be perceived as manipulation. At this stage of the product trial and review, I can assure you that the SEC will be taking a close look at any public communications this company makes. In my experience, company press releases are often "Exhibit A" of shareholder lawsuits. Sure, they can also do good things – inform shareholders and boost share prices – but even the most innocuous-sounding press release carries an inherent risk of backlash, misinterpretation, and/or just plain dissatisfaction from shareholders. I have seen companies send out seemingly mundane and/or routine press releases and have it come back on them in ways they never imagined. Regardless of intent, PR can be very, very dangerous, and right now dangerous is not what NWBO needs. With so much at stake, it's just not worth the risk to be sending out press releases until there is something final and significant to say. I think they are close, but not quite there yet.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:01:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM